Quarterly Metrics: Quick and Current Ratios for Heron Therapeutics Inc (HRTX)

Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Heron Therapeutics Inc’s stock clocked out at $1.77, down -7.33% from its previous closing price of $1.91. In other words, the price has decreased by -$7.33 from its previous closing price. On the day, 2.32 million shares were traded. HRTX stock price reached its highest trading level at $1.885 during the session, while it also had its lowest trading level at $1.76.

Ratios:

To gain a deeper understanding of HRTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.85 and its Current Ratio is at 2.38.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on June 13, 2024, initiated with a Buy rating and assigned the stock a target price of $7.

On April 23, 2024, CapitalOne started tracking the stock assigning a Overweight rating and target price of $6.

Needham reiterated its Buy rating for the stock on March 13, 2024, while the target price for the stock was revised from $4 to $5.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 17 ’23 when Forbes William P bought 25,000 shares for $1.09 per share. The transaction valued at 27,250 led to the insider holds 79,000 shares of the business.

Forbes William P bought 50,000 shares of HRTX for $46,995 on Nov 16 ’23. The EVP, Chief Development Officer now owns 54,000 shares after completing the transaction at $0.94 per share. On Nov 16 ’23, another insider, Collard Craig A, who serves as the Chief Executive Officer of the company, bought 150,000 shares for $0.92 each. As a result, the insider paid 137,970 and bolstered with 186,496 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HRTX now has a Market Capitalization of 289685280 and an Enterprise Value of 379817376. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.97. Its current Enterprise Value per Revenue stands at 2.785 whereas that against EBITDA is -14.597.

Stock Price History:

Over the past 52 weeks, HRTX has reached a high of $3.93, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is -6.53%, while the 200-Day Moving Average is calculated to be -32.06%.

Shares Statistics:

It appears that HRTX traded 2.05M shares on average per day over the past three months and 1481080 shares per day over the past ten days. A total of 150.29M shares are outstanding, with a floating share count of 144.07M. Insiders hold about 5.01% of the company’s shares, while institutions hold 81.13% stake in the company. Shares short for HRTX as of 1728950400 were 30643570 with a Short Ratio of 14.93, compared to 1726185600 on 35441558. Therefore, it implies a Short% of Shares Outstanding of 30643570 and a Short% of Float of 26.119999999999997.

Most Popular